Clinical Trials

The purpose of this study is to validate use of a modified Unified Multiple System Atrophy Rating Scale (UMSARS) that incorporates structured questions and additional instructions, developed by Biohaven Pharmaceuticals based on feedback from the FDA, as the primary outcome variable for assessing clinically meaningful change in Biohaven’s Phase 3 Multiple System Atrophy (MSA) Study BHV3241-301.

The purpose of this study is to evaluate the effectiveness of Lu AF82422 on disease progression in patients with Multiple System Atrophy (MSA).

1. To evaluate whether SSRI use is associated with increased survival time and slower disease progression among patients with MSA.

2. To evaluate whether SSRI use is associated with the presence of clinical respiratory insufficiency such as stridor.

The primary purpose of this study is to understand the influence of sex and gender on pathophysiologic mechanisms of neurodegeneration in Multiple System Atrophy (MSA) in order to determine sex-specific hormonal factors associated with onset of symptoms in MSA.

The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item.

The purpose of this study is to understand why patients with multiple system atrophy, Parkinson’s disease, Parkinson’s disease with autonomic failure, and dementia with Lewy bodies have a fall in blood pressure on standing up. It is believed that different patients develop these symptoms for different reasons. The reasons could be:

• damage to nerve supply to the legs

• the autonomic nerves are not working properly

• the brain is not controlling blood pressure or heart rate properly

This study will look at these different reasons.

The purpose of this research study is to better understand why patients with a disease that causes problems with the autonomic nervous system often have high blood pressure when they lie down. We hope that if we learn more about the cause for this problem, we will be able to treat the problem better in the future.

The goals of the study are to prospectively evaluate clinical and laboratory biomarkers of multiple system atrophy and Parkinson’s disease at early clinical disease, at a premotor stage (PAF), and even at a prodromal stage (RBD).

The primary purpose of this study is to create a Mayo Clinic repository for  neurodegenerative disorders such as Parkinson’s disease (PD), Parkinson’s disease dementia and dementia with Lewy bodies (PDD/DLB), multiple system atrophy (MSA), progressive supranuclear palsy (PSP), cortico-basal degeneration (CBD), and other even rarer forms of neurodegeneration.

The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death.  Comparison of specimens from normal and diseased individuals provide essential clues that lead to a greater understanding of the diseased state which, in turn, will lead to new ideas for therapy.